Difference between revisions of "COVID-19 and emerging viral infections: The case for interferon lambda (DOI: 10.1084/jem.20200653) (Q10304)"
Jump to navigation
Jump to search
(Created claim: has part (P22): Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181), #quickstatements; #temporary_batch_1593026963448) |
(Created claim: has part (P22): References (from DOI: 10.1084/jem.20200653) (Q11182), #quickstatements; #temporary_batch_1593026963448) |
||
| Property / has part | |||
| + | |||
| Property / has part: References (from DOI: 10.1084/jem.20200653) / rank | |||
| + | Normal rank | ||
Latest revision as of 19:29, 24 June 2020
Research article published in J. Exp. Med.; 2020 05 04 ; 217 (5)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
COVID-19 and emerging viral infections: The case for interferon lambda (DOI: 10.1084/jem.20200653)
|
Research article published in J. Exp. Med.; 2020 05 04 ; 217 (5)
|
Statements
J. Exp. Med.; 2020 05 04 ; 217 (5).
COVID-19 and emerging viral infections: The case for interferon lambda (English)
0 references
